ONCAlert | 2018 Gastrointestinal Cancers Symposium
Videos  >  

Phase II Results for Cabozantinib in RET-Rearranged Lung Cancer

Christine M. Lovly, MD, PhD
Published Online:11:59 AM, Mon August 14, 2017

Christine M. Lovly, MD, PhD, assistant professor of medicine (hematology/oncology), assistant professor of cancer biology, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses phase II results for cabozantinib (Cabometyx) in patients with RET-rearranged lung cancer.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.